Abstract
BACKGROUND:
A prognostic model based on clinical parameters for nonsmall cell lung cancer (NSCLC) patients treated with gefitinib (250 mg/day) as a salvage therapy was devised.
METHODS:
Clinical data regarding a total of 316 metastatic or recurrent NSCLC patients who were treated with gefitinib were analyzed.
RESULTS:
Poor prognostic factors for overall survival (OS) by multivariate analysis were an Eastern Cooperative Oncology Group (ECOG) performance status of 2 to 3 (hazards ratio [HR] of 2.07; 95% confidence interval [CI], 1.57โ2.73 [P < .001]), the presence of intraโabdominal metastasis (HR of 1.76; 95% CI, 1.33โ2.34 [P < .001]), elevated serum alkaline phosphatase (HR of 1.50; 95% CI, 1.13โ2.00 [P = .005]), time interval from diagnosis to gefitinib therapy of โค12 months (HR of 1.48; 95% CI, 1.12โ1.95 [P = .005]), low serum albumin (HR of 1.45; 95% CI, 1.09โ1.92 [P = .009]), progressionโfree interval for previous chemotherapy of โค12 weeks (HR of 1.40; 95% CI, 1.0โ1.84 [P = .015]), white blood cell >10,000/ฮผL (HR of 1.38; 95% CI, 1.02โ1.85 [P = .032]), and everโsmoker (HR of 1.33; 95% CI, 1.02โ1.75 [P = .033]). Of the 272 patients applicable to this prognostic model, 41 patients (15%) were categorized as a good prognosis group (0โ1 risk factors), 100 patients (37%) as an intermediate prognosis group (2โ3 risk factors), 81 patients (30%) as a poor prognosis group (4โ5 risk factors), and 50 patients (16%) as a very poor prognosis group (โฅ6 risk factors). The median OS from the time of gefitinib treatment for the good, intermediate, poor, and very poor prognosis groups were 18.0 months, 11.2 months, 4.0 months, and 1.3 months, respectively (P < .001).
CONCLUSIONS:
This prognostic model based on easily available clinical variables would be useful to identify patients who might derive more benefit from gefitinib treatment and to make decisions in clinical practice. Cancer 2009. ยฉ 2009 American Cancer Society.